PL3455257T3 - Przeciwciała anty-pd-l1 - Google Patents

Przeciwciała anty-pd-l1

Info

Publication number
PL3455257T3
PL3455257T3 PL17724263T PL17724263T PL3455257T3 PL 3455257 T3 PL3455257 T3 PL 3455257T3 PL 17724263 T PL17724263 T PL 17724263T PL 17724263 T PL17724263 T PL 17724263T PL 3455257 T3 PL3455257 T3 PL 3455257T3
Authority
PL
Poland
Prior art keywords
antibodies
Prior art date
Application number
PL17724263T
Other languages
English (en)
Inventor
Bruce Keyt
Leonard George Presta
Ramesh Baliga
Original Assignee
Igm Biosciences Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igm Biosciences Inc. filed Critical Igm Biosciences Inc.
Publication of PL3455257T3 publication Critical patent/PL3455257T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL17724263T 2016-05-09 2017-05-09 Przeciwciała anty-pd-l1 PL3455257T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662333643P 2016-05-09 2016-05-09
EP17724263.3A EP3455257B1 (en) 2016-05-09 2017-05-09 Anti-pd-l1 antibodies
PCT/US2017/031791 WO2017196867A1 (en) 2016-05-09 2017-05-09 Anti-pd-l1 antibodies

Publications (1)

Publication Number Publication Date
PL3455257T3 true PL3455257T3 (pl) 2022-01-17

Family

ID=58710168

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17724263T PL3455257T3 (pl) 2016-05-09 2017-05-09 Przeciwciała anty-pd-l1

Country Status (15)

Country Link
US (3) US10954302B2 (pl)
EP (1) EP3455257B1 (pl)
JP (1) JP6979971B2 (pl)
KR (1) KR102343742B1 (pl)
CN (1) CN109311985B (pl)
AU (1) AU2017264683B2 (pl)
CA (1) CA3021669A1 (pl)
DK (1) DK3455257T3 (pl)
ES (1) ES2899361T3 (pl)
HU (1) HUE055972T2 (pl)
IL (1) IL262295B2 (pl)
PL (1) PL3455257T3 (pl)
PT (1) PT3455257T (pl)
SG (1) SG11201809336QA (pl)
WO (1) WO2017196867A1 (pl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250091304A (ko) 2013-03-15 2025-06-20 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
CA2922830A1 (en) 2013-09-05 2015-04-16 Igm Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent ig-m antibodies
AU2015213593B2 (en) 2014-02-10 2020-09-03 Igm Biosciences, Inc. IgA multi-specific binding molecules
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR102380402B1 (ko) 2014-04-03 2022-03-31 아이쥐엠 바이오사이언스 인코포레이티드 변형된 j-사슬
EP3750918A1 (en) 2015-01-20 2020-12-16 IGM Biosciences, Inc. Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
CN115093479A (zh) 2015-03-04 2022-09-23 Igm生物科学股份有限公司 Cd20结合分子及其用途
AU2016233495B2 (en) 2015-03-13 2022-02-24 Cytomx Therapeutics, Inc Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
JP6882184B2 (ja) 2015-03-25 2021-06-02 アイジーエム バイオサイエンシズ インコーポレイテッド 多価ｂ型肝炎ウイルス抗原結合分子およびその使用
WO2016168758A1 (en) 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
DK3355913T3 (da) 2015-09-30 2024-12-02 Igm Biosciences Inc Bindingsmolekyler med modificeret j-kæde
PL3455257T3 (pl) * 2016-05-09 2022-01-17 Igm Biosciences Inc. Przeciwciała anty-pd-l1
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
KR102726248B1 (ko) 2016-07-07 2024-11-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
US11401337B2 (en) 2017-04-07 2022-08-02 Igm Biosciences, Inc. Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function
CA3058966A1 (en) 2017-04-14 2018-10-18 Tollnine, Inc. Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
BR112019025188A2 (pt) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
WO2019096121A1 (en) * 2017-11-17 2019-05-23 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against pd-l1
CN111356702B (zh) * 2017-12-06 2022-07-26 正大天晴药业集团南京顺欣制药有限公司 抗pd-l1抗体及其抗原结合片段
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
MX2020007406A (es) * 2018-01-10 2020-09-14 Jiangsu Hengrui Medicine Co Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
WO2019143837A1 (en) * 2018-01-17 2019-07-25 Apexigen, Inc. Anti-pd-l1 antibodies and methods of use
WO2019169314A1 (en) 2018-03-01 2019-09-06 Igm Biosciences, Inc. IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE
TWI756621B (zh) * 2019-01-25 2022-03-01 大陸商信達生物製藥（蘇州）有限公司 新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體
JP2022521305A (ja) * 2019-02-21 2022-04-06 ユーカー（ベンジン） バイオファーマ カンパニー，リミテッド 抗ｐｄ－ｌ１抗体及びその使用
CA3130794A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
CN114269785A (zh) * 2019-08-15 2022-04-01 Igm生物科学股份有限公司 免疫刺激性多聚体结合分子
CN110746493A (zh) * 2019-09-06 2020-02-04 中国药科大学 一种pd-l1拮抗剂多肽及其应用
CN113121686B (zh) * 2019-12-31 2025-12-02 迈威(上海)生物科技股份有限公司 抗pd-l1抗体及其应用
IL295759A (en) 2020-02-28 2022-10-01 Tallac Therapeutics Inc Transglutaminase mediated coupling
US20230212293A1 (en) 2020-04-22 2023-07-06 Igm Biosciences, Inc. Pd-1 agonist multimeric binding molecules
CN113754775A (zh) * 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 一种抗pd-l1和her2的双特异性抗体
IL298946A (en) 2020-06-18 2023-02-01 Genentech Inc Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
CA3187008A1 (en) * 2020-07-27 2022-02-03 Paul R. Hinton Multimeric coronavirus binding molecules and uses thereof
CN116437944A (zh) * 2020-08-03 2023-07-14 南特细胞公司 Il-15超级激动剂的药物特异性药代动力学测定
JP2024527049A (ja) 2021-07-28 2024-07-19 ジェネンテック， インコーポレイテッド がんを治療するための方法及び組成物
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
CN113943371B (zh) * 2021-11-01 2023-05-05 达石药业(广东)有限公司 一种抗her2/抗pd-l1双功能抗体及其应用
WO2023178253A2 (en) * 2022-03-18 2023-09-21 Igm Biosciences, Inc. Use of a multimeric anti-pd-l1 binding molecule in combination with a monoclonal antibody therapy
IL317449A (en) 2022-06-07 2025-02-01 Genentech Inc Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist
EP4652201A1 (en) * 2023-01-18 2025-11-26 Elpiscience (Suzhou) Biopharma, Ltd. Anti-pdl1 single domain antibody, fusion protein and use thereof
JP2026504180A (ja) 2023-01-30 2026-02-03 カイマブ・リミテッド 抗体

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
WO2006052641A2 (en) 2004-11-05 2006-05-18 Palingen, Inc. Antibody induced cell membrane wounding
HUE065752T2 (hu) * 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
KR101981873B1 (ko) * 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
CA2863714C (en) 2012-02-08 2022-07-05 Igm Biosciences, Inc. Cdim binding proteins and uses thereof
CA2922830A1 (en) 2013-09-05 2015-04-16 Igm Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent ig-m antibodies
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
AU2015213593B2 (en) 2014-02-10 2020-09-03 Igm Biosciences, Inc. IgA multi-specific binding molecules
KR102380402B1 (ko) 2014-04-03 2022-03-31 아이쥐엠 바이오사이언스 인코포레이티드 변형된 j-사슬
ES2753360T3 (es) * 2014-05-29 2020-04-08 Spring Bioscience Corp Anticuerpos contra PD-L1 y usos de los mismos
KR102003754B1 (ko) * 2014-07-03 2019-07-25 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
WO2016022630A1 (en) * 2014-08-05 2016-02-11 Jiping Zha Anti-pd-l1 antibodies
EP3750918A1 (en) 2015-01-20 2020-12-16 IGM Biosciences, Inc. Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
CN115093479A (zh) 2015-03-04 2022-09-23 Igm生物科学股份有限公司 Cd20结合分子及其用途
JP6882184B2 (ja) 2015-03-25 2021-06-02 アイジーエム バイオサイエンシズ インコーポレイテッド 多価ｂ型肝炎ウイルス抗原結合分子およびその使用
WO2016168758A1 (en) 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
DK3355913T3 (da) 2015-09-30 2024-12-02 Igm Biosciences Inc Bindingsmolekyler med modificeret j-kæde
PL3455257T3 (pl) * 2016-05-09 2022-01-17 Igm Biosciences Inc. Przeciwciała anty-pd-l1
US20190330374A1 (en) 2016-07-20 2019-10-31 Igm Biosciences, Inc. Multimeric ox40 binding molecules and uses thereof
EP3496536A4 (en) 2016-07-20 2020-02-12 IGM Biosciences, Inc. MULTIMERE CD40-BINDING MOLECULES AND USES THEREOF
US20190330360A1 (en) 2016-07-20 2019-10-31 Igm Biosciences, Inc. Multimeric gitr binding molecules and uses thereof
US20190338040A1 (en) 2016-07-20 2019-11-07 Igm Biosciences, Inc. Multimeric cd137/4-1bb binding molecules and uses thereof
US11401337B2 (en) 2017-04-07 2022-08-02 Igm Biosciences, Inc. Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function
US20200392239A1 (en) 2018-02-26 2020-12-17 Igm Biosciences, Inc. Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer
WO2019169314A1 (en) 2018-03-01 2019-09-06 Igm Biosciences, Inc. IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE
KR20210083260A (ko) 2018-10-23 2021-07-06 아이쥐엠 바이오사이언스 인코포레이티드 다가 IgM- 및 IgA-Fc 기반 결합 분자
US20220106398A1 (en) 2019-02-08 2022-04-07 Igm Biosciences, Inc. Anti-gitr antigen-binding domains and uses thereof

Also Published As

Publication number Publication date
EP3455257A1 (en) 2019-03-20
ES2899361T3 (es) 2022-03-11
SG11201809336QA (en) 2018-11-29
HUE055972T2 (hu) 2022-01-28
US20190338031A1 (en) 2019-11-07
AU2017264683A1 (en) 2018-11-01
EP3455257B1 (en) 2021-09-22
KR20190003989A (ko) 2019-01-10
CN109311985B (zh) 2022-09-30
CA3021669A1 (en) 2017-11-16
US20210163600A1 (en) 2021-06-03
US20240002514A1 (en) 2024-01-04
DK3455257T3 (da) 2021-11-01
JP2019519492A (ja) 2019-07-11
IL262295B1 (en) 2023-05-01
AU2017264683B2 (en) 2024-02-29
JP6979971B2 (ja) 2021-12-15
IL262295B2 (en) 2023-09-01
KR102343742B1 (ko) 2021-12-24
PT3455257T (pt) 2021-12-06
US10954302B2 (en) 2021-03-23
IL262295A (en) 2018-12-31
WO2017196867A1 (en) 2017-11-16
CN109311985A (zh) 2019-02-05

Similar Documents

Publication Publication Date Title
HUS2500002I1 (hu) Újszerû anti-PD-L1 antitestek
ZA201900353B (en) Anti-pd-l1 antibodies
IL262295A (en) Antibodies against pd-l1
HUS2500024I1 (hu) ANTI-PD-1 ellenanyagok
IL255727A (en) Novel anti-pd-l1 antibodies
ZA201900373B (en) Anti-tim-3 antibodies
PL3512547T3 (pl) Przeciwciała anty-pd-1
SG11201705552QA (en) Anti-pd-l1 antibodies
IL250415A0 (en) Antibodies against pd-l1
SG10201603721TA (en) Anti-CTLA-4 Antibodies
SG10201601719RA (en) Anti-LAG-3 Antibodies
GB201601073D0 (en) Antibodies
GB201621439D0 (en) IL-11Ra Antibodies
ZA201807167B (en) Humanized anti-il-1r3 antibodies
GB201610044D0 (en) Antibodies
GB201616699D0 (en) Antibodies
ZA201808317B (en) Anti-tnfrsf25 antibodies
GB201603291D0 (en) Antibodies
PT3484921T (pt) Anticorpos anti-il-22r
GB201511196D0 (en) Monoclonal antibodies
GB201622197D0 (en) Antibodies
GB201620414D0 (en) Antibodies
GB201615224D0 (en) Antibodies
GB201613158D0 (en) Antibodies
GB201612437D0 (en) Anti-lag-3 antibodies